Patents by Inventor Jeffrey T. L. Smith
Jeffrey T. L. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210309725Abstract: Methods for treatment of most bothersome symptom (MBS) associated with migraine are provided. Exemplary methods provide improvement in MBS associated with migraine within 1 month of administration og anti-CGRP antibodies of the invention. Also provided are methods for improvement of patient impression of change (PGIC) associated with migraine. Exemplary methods comprise administration of an anti-CGRP antagonistic antibody to a patient in need thereof.Type: ApplicationFiled: April 28, 2020Publication date: October 7, 2021Inventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman
-
Patent number: 11117960Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: GrantFiled: December 9, 2019Date of Patent: September 14, 2021Assignee: H. LUNDBECK A/SInventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
-
Publication number: 20210277106Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.Type: ApplicationFiled: March 16, 2021Publication date: September 9, 2021Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRIX, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
-
Publication number: 20210246201Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: November 11, 2020Publication date: August 12, 2021Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T.L. Smith
-
Publication number: 20210221884Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.Type: ApplicationFiled: January 8, 2019Publication date: July 22, 2021Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRICKS, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
-
Publication number: 20210179688Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: ApplicationFiled: December 15, 2020Publication date: June 17, 2021Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRIX, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
-
Patent number: 11027018Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.Type: GrantFiled: February 13, 2019Date of Patent: June 8, 2021Assignees: The University of Iowa Research Foundation, H. LUNDBECK A/SInventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
-
Patent number: 10981984Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.Type: GrantFiled: December 12, 2018Date of Patent: April 20, 2021Assignees: H. LUNDBECK A/S, The University of Iowa Research FoundationInventors: Adisa Kuburas, Bianca Mason, Levi P. Sowers, Andrew F. Russo, Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendricks, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10981985Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.Type: GrantFiled: February 11, 2020Date of Patent: April 20, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Publication number: 20210107975Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: ApplicationFiled: March 18, 2020Publication date: April 15, 2021Inventors: JEFFREY T.L. SMITH, RANDALL C. SCHATZMAN, MARK LITTON, JOHN LATHAM
-
Patent number: 10975135Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: GrantFiled: February 11, 2020Date of Patent: April 13, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10968268Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: GrantFiled: February 11, 2020Date of Patent: April 6, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10954285Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: GrantFiled: February 11, 2020Date of Patent: March 23, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10913783Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: GrantFiled: April 14, 2017Date of Patent: February 9, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10913794Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 17, 2017Date of Patent: February 9, 2021Assignee: VITAERIS INC.Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 10899834Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.Type: GrantFiled: April 15, 2016Date of Patent: January 26, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10875917Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: September 14, 2018Date of Patent: December 29, 2020Assignee: VITAERIS, INC.Inventor: Jeffrey T. L. Smith
-
Patent number: 10858424Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.Type: GrantFiled: September 14, 2017Date of Patent: December 8, 2020Assignee: ALDERBIO HOLDINGS LLCInventor: Jeffrey T. L. Smith
-
Patent number: 10844116Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.Type: GrantFiled: April 15, 2016Date of Patent: November 24, 2020Assignees: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, H. LUNDBECK A/SInventors: Adisa Kuburas, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren, Bianca Mason, Levi P. Sowers, Andrew F. Russo, Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix
-
Publication number: 20200354446Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: ApplicationFiled: March 19, 2020Publication date: November 12, 2020Inventors: Jeffrey T.L. Smith, John A. Latham, Mark Litton, Randall Schatzman